WO2002043756A3 - Method for obtaining antigenic aggregates and the use thereof in formulations - Google Patents

Method for obtaining antigenic aggregates and the use thereof in formulations Download PDF

Info

Publication number
WO2002043756A3
WO2002043756A3 PCT/CU2001/000009 CU0100009W WO0243756A3 WO 2002043756 A3 WO2002043756 A3 WO 2002043756A3 CU 0100009 W CU0100009 W CU 0100009W WO 0243756 A3 WO0243756 A3 WO 0243756A3
Authority
WO
WIPO (PCT)
Prior art keywords
structures
resulting
aggregate
formulations
antigenic
Prior art date
Application number
PCT/CU2001/000009
Other languages
Spanish (es)
French (fr)
Other versions
WO2002043756A2 (en
Inventor
Rubido Julio Cesar Aguilar
Arias Eduardo Penton
Dina Tleugabulova
Mensies Minerva Sewer
Gonzalez Verena Lucila Muzio
Nieto Gerardo Enrique Guillen
Bernard Iloki Assanga Simon
Ricondo Luis Javier Cruz
Cama Viviana Falcon
Hernandez Yanet Tambara
Original Assignee
Ct Ingenieria Genetica Biotech
Rubido Julio Cesar Aguilar
Arias Eduardo Penton
Dina Tleugabulova
Mensies Minerva Sewer
Gonzalez Verena Lucila Muzio
Nieto Gerardo Enrique Guillen
Bernard Iloki Assanga Simon
Ricondo Luis Javier Cruz
Cama Viviana Falcon
Hernandez Yanet Tambara
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DE60141978T priority Critical patent/DE60141978D1/en
Application filed by Ct Ingenieria Genetica Biotech, Rubido Julio Cesar Aguilar, Arias Eduardo Penton, Dina Tleugabulova, Mensies Minerva Sewer, Gonzalez Verena Lucila Muzio, Nieto Gerardo Enrique Guillen, Bernard Iloki Assanga Simon, Ricondo Luis Javier Cruz, Cama Viviana Falcon, Hernandez Yanet Tambara filed Critical Ct Ingenieria Genetica Biotech
Priority to AU2002221518A priority patent/AU2002221518B2/en
Priority to AT01998363T priority patent/ATE465752T1/en
Priority to KR1020037007094A priority patent/KR100873675B1/en
Priority to CA2429543A priority patent/CA2429543C/en
Priority to JP2002545726A priority patent/JP4974441B2/en
Priority to US10/433,492 priority patent/US20040202676A1/en
Priority to BRPI0115859-7 priority patent/BRPI0115859B8/en
Priority to AU2151802A priority patent/AU2151802A/en
Priority to EP01998363A priority patent/EP1346727B1/en
Publication of WO2002043756A2 publication Critical patent/WO2002043756A2/en
Publication of WO2002043756A3 publication Critical patent/WO2002043756A3/en
Priority to US11/870,088 priority patent/US20090104223A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

The invention relates to a method for obtaining aggregate antigenic structures that are capable of enhancing an immune response to aggregate antigens administered systemically and/or mucosally generating powerful immune responses and to the chemical structures resulting from the application of said method, to the formulations obtained from said structures and to their use. The method describes the obtention of novel aggregate antigenic structures by using aggregating, delipidating or oxidating agents or compounds enabling the release of lipids from the particles and their heterogeneous aggregation, wherein aggregates with particle sizes of between 30 and 500 nm are subsequently selected by means of a molecular exclusion process. The aggregation state can also be provoked inside the yeast by changing incubation conditions. The resulting structures can be used conveniently adjuvated or in a formulation in which several antigens can be introduced, wherein synergism between said components is found with respect to the immunogenicity of the response obtained. The preparation may also contain stabilizers and preservatives. The resulting antigenic structures can be used in the pharmaceutical industry as preventive or therapeutic vaccine formulations both for human and veterinary use and as part of diagnostic systems.
PCT/CU2001/000009 2000-12-01 2001-11-29 Method for obtaining antigenic aggregates and the use thereof in formulations WO2002043756A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
JP2002545726A JP4974441B2 (en) 2000-12-01 2001-11-29 Methods for obtaining antigenic aggregates and their use in formulations
AU2002221518A AU2002221518B2 (en) 2000-12-01 2001-11-29 Method for obtaining antigenic aggregates and the use thereof in formulations
AT01998363T ATE465752T1 (en) 2000-12-01 2001-11-29 METHOD FOR OBTAINING DELIPIDATED ANTIGEN AGGREGATES FROM HEPATITIS B AND THEIR USE
KR1020037007094A KR100873675B1 (en) 2000-12-01 2001-11-29 Method for obtaining antigenic aggregates and the use thereof in formulations
CA2429543A CA2429543C (en) 2000-12-01 2001-11-29 Method for obtaining antigenic aggregates and the use thereof in formulations
DE60141978T DE60141978D1 (en) 2000-12-01 2001-11-29 METHOD FOR OBTAINING DELIPIDATED ANTIGENIC AGGREGATES OF HEPATITIS B AND THEIR USE
US10/433,492 US20040202676A1 (en) 2000-12-01 2001-11-29 Method for obtaining antigenic aggregates and the use thereof in formulations
EP01998363A EP1346727B1 (en) 2000-12-01 2001-11-29 Method for obtaining delipidated hepatitis b antigenic aggregates and their use thereof
AU2151802A AU2151802A (en) 2000-12-01 2001-11-29 Method for obtaining antigenic aggregates and the use thereof in formulations
BRPI0115859-7 BRPI0115859B8 (en) 2000-12-01 2001-11-29 method of obtaining highly immunogenic aggregated antigenic structures, aggregated antigenic structure, vaccine formulation and uses of an antigenic structure and vaccine formulations
US11/870,088 US20090104223A1 (en) 2000-12-01 2007-10-10 Method for Obtaining Antigenic Aggregates and the Use Thereof in Formulations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU20000279A CU23002A1 (en) 2000-12-01 2000-12-01 METHOD OF OBTAINING ANTIGENIC AGGREGATES AND THEIR USE IN FORMULATIONS
CU2000-0279 2000-12-01

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/870,088 Division US20090104223A1 (en) 2000-12-01 2007-10-10 Method for Obtaining Antigenic Aggregates and the Use Thereof in Formulations

Publications (2)

Publication Number Publication Date
WO2002043756A2 WO2002043756A2 (en) 2002-06-06
WO2002043756A3 true WO2002043756A3 (en) 2003-01-09

Family

ID=5459569

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CU2001/000009 WO2002043756A2 (en) 2000-12-01 2001-11-29 Method for obtaining antigenic aggregates and the use thereof in formulations

Country Status (17)

Country Link
US (2) US20040202676A1 (en)
EP (1) EP1346727B1 (en)
JP (1) JP4974441B2 (en)
KR (1) KR100873675B1 (en)
CN (1) CN1253206C (en)
AR (1) AR031437A1 (en)
AT (1) ATE465752T1 (en)
AU (2) AU2002221518B2 (en)
BR (1) BRPI0115859B8 (en)
CA (1) CA2429543C (en)
CU (1) CU23002A1 (en)
DE (1) DE60141978D1 (en)
ES (1) ES2342150T3 (en)
PT (1) PT1346727E (en)
RU (1) RU2266754C2 (en)
WO (1) WO2002043756A2 (en)
ZA (1) ZA200303948B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23405A1 (en) * 2003-10-20 2009-08-04 Ct Ingenieria Genetica Biotech PHARMACEUTICAL COMPOSITIONS FOR THERAPEUTIC USE
EP1652914A1 (en) * 2004-10-27 2006-05-03 Berna Biotech AG Virosome particles comprising antigens from influenza virus and Hepatitis B virus
PL1802746T3 (en) 2004-10-27 2011-10-31 Crucell Switzerland Ag Virosome particles comprising antigens from influenza virus and hepatitis b virus
EP1917029B1 (en) * 2005-07-27 2013-01-23 Eli Lilly And Company A method of treating cancer cells to create a modified cancer cell that provokes an immunogenic response
CU23740A1 (en) * 2009-09-29 2011-12-28 Ct Ingenieria Genetica Biotech METHOD OF OBTAINING A FORMATION OF ANTIGENS FROM THE HEPATITIS B VIRUS
AR107262A1 (en) 2016-01-27 2018-04-11 Lilly Co Eli INACTIVATION OF PATHOGENS BY DELIPIDATION
KR20180125985A (en) 2016-03-31 2018-11-26 센트로 데 인제니에리아 제네티카 와이 바이오테크놀로지아 A pharmaceutical composition comprising a surface of a hepatitis B virus and a nucleocapsid antigen

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0174759A1 (en) * 1984-08-22 1986-03-19 Connaught Laboratories Limited Multispecific immunogenic proteins
EP0231039A1 (en) * 1986-01-14 1987-08-05 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Process for preparing immunological complexes and pharmaceutical composition containing these complexes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728804A (en) * 1995-06-02 1998-03-17 Research Corporation Technologies, Inc. Use of cyclodextrins for protein renaturation
JP2004500868A (en) * 2000-06-22 2004-01-15 セルテック　ファーマスーティカルズ　リミテッド Modification of hepatitis B core antigen
US8092734B2 (en) * 2004-05-13 2012-01-10 Aptina Imaging Corporation Covers for microelectronic imagers and methods for wafer-level packaging of microelectronics imagers

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0174759A1 (en) * 1984-08-22 1986-03-19 Connaught Laboratories Limited Multispecific immunogenic proteins
EP0231039A1 (en) * 1986-01-14 1987-08-05 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Process for preparing immunological complexes and pharmaceutical composition containing these complexes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BABAEVA E E ET AL: "ANTIGENIC DETERMINANTS OF NORMAL SERUM PROTEINS ASSOCIATED WITH HEPATITIS B VIRUS HEPATITIS B SURFACE ANTIGEN", VOPROSY VIRUSOLOGII, no. 4, 1981, pages 442 - 446, XP002209718, ISSN: 0507-4088 *

Also Published As

Publication number Publication date
ATE465752T1 (en) 2010-05-15
JP4974441B2 (en) 2012-07-11
BRPI0115859B8 (en) 2021-05-25
CN1253206C (en) 2006-04-26
US20040202676A1 (en) 2004-10-14
BR0115859A (en) 2003-12-30
CN1477972A (en) 2004-02-25
ZA200303948B (en) 2004-03-30
JP2004529861A (en) 2004-09-30
CU23002A1 (en) 2004-11-18
RU2266754C2 (en) 2005-12-27
EP1346727B1 (en) 2010-04-28
DE60141978D1 (en) 2010-06-10
CA2429543A1 (en) 2003-05-20
US20090104223A1 (en) 2009-04-23
KR100873675B1 (en) 2008-12-11
EP1346727A2 (en) 2003-09-24
PT1346727E (en) 2010-05-21
KR20030068161A (en) 2003-08-19
CA2429543C (en) 2012-07-10
ES2342150T3 (en) 2010-07-02
AU2002221518B2 (en) 2006-06-01
WO2002043756A2 (en) 2002-06-06
AU2151802A (en) 2002-06-11
BRPI0115859B1 (en) 2020-10-13
AR031437A1 (en) 2003-09-24

Similar Documents

Publication Publication Date Title
RU2349342C2 (en) Meningococcal vaccines for administration via mucosa
DE69630033T2 (en) IMMUNOLOGICAL COMBINATION AGENTS AND RELATED METHODS
Weeratna et al. CpG DNA induces stronger immune responses with less toxicity than other adjuvants
WO2000050006A3 (en) Microemulsions with adsorbed macromoelecules and microparticles
ZA200600151B (en) Quil A fraction with low toxicity and use thereof
WO2001060402A3 (en) Proteosome influenza vaccine
EP1490106B1 (en) Use of a lipopeptide or lipoprotein as an adjuvant in therapeutic or prophylactic vaccinations
WO2003051394A3 (en) Calcium phosphate particles as mucosal adjuvants
US20140178431A1 (en) Lipid and nitrous oxide combination as adjuvant for the enhancement of the efficacy of vaccines
Eng et al. The potential of polyphosphazenes for delivery of vaccine antigens and immunotherapeutic agents
WO2002043756A3 (en) Method for obtaining antigenic aggregates and the use thereof in formulations
WO2003059385A3 (en) Hiv vaccine and method of use
AU769375B2 (en) Vaccine formulation
Burakova et al. Food-grade saponin extract as an emulsifier and immunostimulant in emulsion-based subunit vaccine for pigs
AU769390B2 (en) Vaccine composition
AU5441299A (en) Method for inducing a cell-mediated immune response and parenteral vaccine formulations therefor
EP2174665A3 (en) Compositions and methods for activating innate and allergic immunity
Kreuter et al. Protection induced by inactivated influenza virus vaccines with polymethylmethacrylate adjuvants
Alshanqiti et al. Adjuvants for Clostridium tetani and Clostridium diphtheriae vaccines updating
DE69018702T2 (en) Process for the preparation of an anti-caries vaccine from Streptococcus mutans and vaccine composition for caries in the form of nose drops.
WO2000062802A3 (en) Vaccine comprising rsv antigen and cpg oligonucleotide
WO2002036160A3 (en) Method for obtaining antigenic structures enhancing specific cross reactivity
Donnelly New developments in adjuvants
Cameron Comparative efficacy of six Brucella vaccines in guinea-pigs
TH55920B (en) Method for obtaining antigenic clump And its use in the formula

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 770/DELNP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2429543

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003/03948

Country of ref document: ZA

Ref document number: 200303948

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2002221518

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020037007094

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 018198236

Country of ref document: CN

Ref document number: 2002545726

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2001998363

Country of ref document: EP

ENP Entry into the national phase

Ref country code: RU

Ref document number: RU A

WWP Wipo information: published in national office

Ref document number: 1020037007094

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2001998363

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10433492

Country of ref document: US